Fig. 1From: Cardiovascular disease in Alpha 1 antitrypsin deficiency: an observational study assessing the role of neutrophil proteinase activity and the suitability of validated screening toolsPulse wave velocity and QRISK2® score. aPWV (A) and a QRISK2® score (B) was calculated per participant as described in the methods at the study visit using provided demographic and laboratory measures. In this figure the aPWV is unadjusted for age or smoking history, while QRISK2® automatically adjusts for these factors. QRISK2® score does not include those with known CVD. Each dot represents one measure. Median and IQR are shown. For both graphs, groups were compared with a Kruskal–Wallis test and Dunn’s Multiple Comparison test was then performed. A; * = p = 0.0225, *** = p = 0.0003, **** = p < 0.0001. For B; AATD vs HC p = 0.0005, COPD vs HC p = 0.0004, **** = p < 0.0001Back to article page